Based on the provided data, the forecasted sales values (in Million US Dollars PPP) of respiratory system medicines in Australia are as follows:
- 2024: 883.1
- 2025: 926.5
- 2026: 969.7
- 2027: 1010.0
- 2028: 1060.0
The year-on-year variations in percentage are:
- 2025: 4.91%
- 2026: 4.67%
- 2027: 4.15%
- 2028: 4.95%
The Compound Annual Growth Rate (CAGR) over the forecast period (2024-2028) averages at approximately 4.67% per annum.
Trends to Watch: Future trends to monitor include the potential impacts of regulatory changes, innovation in treatment options, and the prevalence of respiratory conditions. Market dynamics, such as the emergence of new market entrants and changes in patient demographics, will also be critical to consider.
